Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh
Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., said on Thursday it has received the Establishment Inspection Report (EIR) from the USFDA (the United States Food and Drug Administration) for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh
Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur
Lupin gets Establishment Inspection Report from USFDA for Pithampur facility unit; stock falls 1.88%
Drug firm Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its Pithampur facility in Madhya Pradesh.
Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.
Shares of Sun Pharmaceutical Industries on Wednesday gained nearly 4 percent after the company received establishment inspection report (EIR) from the US health regulator for its Halol facility in Gujarat
Sun Pharma receives EIR for its crucial Halol plant in Gujarat, US health regulator clears drug major
Sun Pharmaceutical Industries said it has received establishment inspection report (EIR) from US health regulator for its Halol facility in Gujarat
The EIR report is given to an establishment after the completion of an inspection by the USFDA
The USFDA released a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed